Hansa Biopharma: Confirms a record quarter Idefirix - Redeye

Hansa’s actual outcome after the trading outcome confirms that Idefirix records European product sales of SEK 43m in Q4. In Q4, Hansa experienced support from countries like the UK, Spain and Germany, including added guidelines and recommendations to support additional countries. During 2024, Hansa is also expecting additional sales related to the Eurotransplant program. Hansa's saving program will amount to SEK 75-80m annually when fully implemented later in 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/974249/hansa-biopharma-confirms-a-record-quarter-idefirix?utm_source=finwire&utm_medium=RSS